Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Blood (2020) 136 (24): 2812–2823.

https://doi.org/10.1182/blood.2020006158

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Blood (2019) 133 (7): 676–687.

https://doi.org/10.1182/blood-2018-08-869008

Published: 2019

Includes: Supplemental data

Journal Articles

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Lin Tang, PhD, Anna Dolnik, PhD, Kyle J. MacBeth, PhD, Hervé Dombret, Prof., John F. Seymour, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, C.L. Beach, PharmD, Hartmut Döhner, MD, Lars Bullinger, MD

Blood (2016) 128 (22): 2859.

https://doi.org/10.1182/blood.V128.22.2859.2859

Published: 2016

Journal Articles

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Valeria Santini, MD, Pierre Fenaux, MD PhD, Aristoteles Giagounidis, Uwe Platzbecker, MD, Alan F List, MD, Jianhua Zhong, PhD, Chengqing Wu, PhD, Konstantinos Mavrommatis, C.L. Beach, PharmD, Albert Hoenekopp, MD, Kyle J. MacBeth, PhD

Blood (2016) 128 (22): 225.

https://doi.org/10.1182/blood.V128.22.225.225

Published: 2016

Journal Articles

Lenalidomide Promotes Degradation of Casein Kinase 1a (CK1a) through Cereblon: Implications for the Efficacy of Lenalidomide in MDS and AML

Paul Hollenbach, Ling Lu, BS, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Kyle J MacBeth, PhD

Blood (2014) 124 (21): 3606.

https://doi.org/10.1182/blood.V124.21.3606.3606

Published: 2014

Journal Articles

A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes

Jing Fang, MD PhD, Xiaona Liu, BSc, Lyndsey Bolanos, BSc, Brenden Barker, BSc, Carmela Rigolino, BSc, Agostino Cortelezzi, MD, Esther Natalie Oliva, MD, Kyle J MacBeth, PhD, Kakajan Komurov, PhD, Daniel T Starczynowski, PhD

Blood (2014) 124 (21): 1898.

https://doi.org/10.1182/blood.V124.21.1898.1898

Published: 2014

Journal Articles

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

Eric Laille, MS, Tao Shi, PhD, Guillermo Garcia-Manero, MD, Christopher R. Cogle, MD, Steven D. Gore, MD, Keshava J. Kumar, PhD, Barry S. Skikne, MD, Kyle J. MacBeth, PhD

Blood (2012) 120 (21): 1337.

https://doi.org/10.1182/blood.V120.21.1337.1337

Published: 2012

Journal Articles

Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine

John Powers, B.S., Eva Sahakian, Ph.D, Jason A Dubovsky, Ph.D, Tyler Farnum, Emmanuel Berchmans, B.S., Douglas G McNeel, MD, Barry S. Skikne, MD, Kyle J MacBeth, Rami S. Komrokji, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2012) 120 (21): 3828.

https://doi.org/10.1182/blood.V120.21.3828.3828

Published: 2012

Journal Articles

Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine,

Tao Shi, PhD, Ludmila Danilova, PhD, Xiaolong Luo, PhD, Lela M. Lucy, MS, CL Beach, PharmD, Leslie Cope, PhD, James G. Herman, MD, Kyle J. MacBeth, PhD

Blood (2011) 118 (21): 3815.

https://doi.org/10.1182/blood.V118.21.3815.3815

Published: 2011

Journal Articles

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

Steven D. Gore, MD, Christopher R. Cogle, MD, Barry Skikne, MD, Eric Laille, MS, Tao Shi, PhD, Kyle J. MacBeth, PhD, Heidi Giordano, MA, MBA, Guillermo Garcia-Manero

Blood (2011) 118 (21): 1546.

https://doi.org/10.1182/blood.V118.21.1546.1546

Published: 2011

Journal Articles

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Elias J. Jabbour, MD, M. Renee Ward, MD, PhD, Kyle J. MacBeth, PhD, Eric Laille, MS, Heidi Giordano, MA, Hagop M. Kantarjian, MD, Barry S. Skikne, MD

Blood (2010) 116 (21): 603.

https://doi.org/10.1182/blood.V116.21.603.603

Published: 2010

Journal Articles

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

Kyle J MacBeth, Eric Laille, Yuhong Ning, Christopher R. Cogle, MD, Barry Skikne, Steven D. Gore, MD, Guillermo Garcia-Manero, MD, M. Renee Ward, MD, PhD

Blood (2009) 114 (22): 1772.

https://doi.org/10.1182/blood.V114.22.1772.1772

Published: 2009

Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Barry Skikne, Christopher R. Cogle, MD, Yuhong Ning, Kyle J MacBeth, Eric Laille, M. Renee Ward, MD, PhD

Blood (2009) 114 (22): 117.

https://doi.org/10.1182/blood.V114.22.117.117

Published: 2009

Journal Articles

The Histone Deacetylase Inhibitor MGCD0103 Down Regulates CD30, Activates NF-Kb, and Synergizes with Proteasome Inhibitors by HDAC6 Independent Mechanism in Hodgkin Lymphoma.

Daniela Buglio, MD, Vidya Mamidipudi, Noor M Khaskhely, MD, PhD, Annunziata Gloghini, Antonino Carbone, MD, Carla Heise, Jeffrey M. Besterman, PhD, BSc, Robert E Martell, Kyle J MacBeth, Anas Younes, MD

Blood (2009) 114 (22): 3735.

https://doi.org/10.1182/blood.V114.22.3735.3735

Published: 2009

NARROW

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Lenalidomide Promotes Degradation of Casein Kinase 1a (CK1a) through Cereblon: Implications for the Efficacy of Lenalidomide in MDS and AML

A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine

Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine,

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

The Histone Deacetylase Inhibitor MGCD0103 Down Regulates CD30, Activates NF-Kb, and Synergizes with Proteasome Inhibitors by HDAC6 Independent Mechanism in Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only